Dividend Investing Ideas Center
Have you ever wished for the safety of bonds, but the return potential...
Eli Lilly (LLY ) reported its fourth quarter earnings before the opening bell on Friday morning, posting lower revenues and higher adjusted EPS than last year’s same period.
LLY chairman, president and CEO John C. Lechleiter, Ph.D. had the following comments: “While Lilly’s fourth-quarter 2014 results continue to reflect the impact of patent expirations, we are moving to a period of growth led by diabetes, oncology and animal health. Despite the loss of significant revenue for Cymbalta and Evista following the expiration of our U.S. patents, we saw strong performance from many other products. At the same time, we made excellent progress with our innovation-based strategy, and we continue to advance our pipeline. Throughout the balance of this decade, we aim to drive revenue growth and expand margins as we offer new medicines to the people who need them.”
Eli Lilly will pay its next quarterly dividend of 50 cents on March 10. The stock goes ex-dividend on February 11.
Eli Lilly stock was inactive in pre-market trading. YTD, the stock is up 4.52%.